ÂÜÀòÂÒÂ×

Cort Cramer is Senior Director, Nonclinical Development & Toxicology at Prothelia. Prior to Prothelia, he served as Senior Director, Toxicology at Apellis Pharmaceuticals. At Apellis, Cort led the Nonclinical Development group through commercialization of pegcetacoplan (APL-2) for paroxysmal nocturnal hemoglobinuria, pre-commercialization of pegcetacoplan for geographic atrophy and development of Apellis’ pipeline for numerous complement-mediated diseases. Prior to joining Apellis, Cort served as a toxicologist in support of drug development efforts at Alkermes and Enanta Pharmaceuticals. Cort has over 15 years of experience in the pharmaceutical, biotechnology and CRO/service industries and has contributed to the development of numerous clinical-stage products. Cort received a B.S. in Biology from Syracuse University, and a M.S. in Toxicology from Northeastern University.